Celcuity submits REVTORPYK sNDA, opening PIK3CA-mutant label expansion

The key milestone was expected, not a surprise. The relevant benchmark here is timing rather than an earnings consensus: Celcuity had already told investors it planned to submit the PIK3CA-mutant sNDA during the third quarter, so the August 26 filing confirms execution of that plan rather than creating a new regulatory catalyst.

The filing expands the commercial opportunity if approved. REVTORPYK is already approved for HR+/HER2- advanced breast cancer without a detected PIK3CA mutation; this submission seeks access to the mutant population as well. The filing states that Celcuity “today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”)” 〔0〕.

The supporting efficacy is strong, but the data were already known. In the PIK3CA-mutant cohort, the triplet produced median PFS of 11.1 months versus 5.6 months for alpelisib plus fulvestrant, while the doublet produced 11.3 months versus 5.6 months. The filing says, “Median progression-free survival (“PFS”) was 11.1 months with the REVTORPYK-triplet versus 5.6 months with alpelisib plus fulvestrant.” 〔1〕 Those results make the label expansion strategically meaningful, but they do not represent fresh trial data in this filing.

The net read is confirmation rather than a beat. The application converts previously released positive Phase 3 data into a formal FDA review, with approval still required and no review timeline provided. Safety was not presented as a new problem—the filing says, “The safety data for both regimens were generally consistent with previously reported data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial.”